We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.
BJU International 2012 June
UNLABELLED: Study Type - Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? While cytoreductive nephrectomy is associated with a survival benefit in the context of metastatic renal cell carcinoma, the rates of morbidity and perioperative mortality remain non-negligible. For example, perioperative mortality may be as high as 21% in elderly patients. The study shows that perioperative death amongst the elderly was substantially lower than what was previously reported from a single institutional report. Nonetheless, postoperative adverse outcomes were non-negligible in elderly patients relative to their younger counterparts. In consequence, these rates should be discussed at informed consent and a rigorous patient selection remains essential.
OBJECTIVE: • To examine the rate of perioperative mortality (PM), and other adverse outcomes in 'elderly' patients treated with cytoreductive nephrectomy (CNT).
MATERIAL AND METHODS: • Patients who underwent CNT for metastatic renal cell carcinoma were abstracted from the Nationwide Inpatient Sample (1998-2007). 'Elderly' was defined as ≥ 75 years, according to previous definition. • Endpoints consisted of PM, intraoperative and postoperative complications, blood transfusions and length of stay. • We adjusted for the effect of elderly status within five separate logistic regression models. Covariates consisted of comorbidity, race, gender, year of surgery and hospital region.
RESULTS: • Overall, CNT was performed in 504 (15.3%) elderly patients and in 2796 (84.7%) 'younger' patients (<75 years). • The rate of PM was 4.8% in elderly patients vs 1.9% in the younger patients (P < 0.001). Similarly, the rates of blood transfusions (29.8 vs 21.5%), postoperative complications (27.8 vs 22.8%), and prolonged length of stay (≥ 8 days) were higher in the elderly (45.0 vs 32.0%; all P < 0.001). • In multivariable analyses, elderly patients were 2.2-, 1.5-, and 1.6 fold more likely to experience PM, to receive a blood transfusion and to be hospitalized ≥ 8 days than the younger patients.
CONCLUSIONS: • Although the rate of PM was substantially lower than 21%, elderly patients are significantly more likely to die after this type of surgery, to receive a transfusion, and to experience a prolonged length of stay. • These facts and figures should be discussed at informed consent and a rigorous patient selection is essential.
OBJECTIVE: • To examine the rate of perioperative mortality (PM), and other adverse outcomes in 'elderly' patients treated with cytoreductive nephrectomy (CNT).
MATERIAL AND METHODS: • Patients who underwent CNT for metastatic renal cell carcinoma were abstracted from the Nationwide Inpatient Sample (1998-2007). 'Elderly' was defined as ≥ 75 years, according to previous definition. • Endpoints consisted of PM, intraoperative and postoperative complications, blood transfusions and length of stay. • We adjusted for the effect of elderly status within five separate logistic regression models. Covariates consisted of comorbidity, race, gender, year of surgery and hospital region.
RESULTS: • Overall, CNT was performed in 504 (15.3%) elderly patients and in 2796 (84.7%) 'younger' patients (<75 years). • The rate of PM was 4.8% in elderly patients vs 1.9% in the younger patients (P < 0.001). Similarly, the rates of blood transfusions (29.8 vs 21.5%), postoperative complications (27.8 vs 22.8%), and prolonged length of stay (≥ 8 days) were higher in the elderly (45.0 vs 32.0%; all P < 0.001). • In multivariable analyses, elderly patients were 2.2-, 1.5-, and 1.6 fold more likely to experience PM, to receive a blood transfusion and to be hospitalized ≥ 8 days than the younger patients.
CONCLUSIONS: • Although the rate of PM was substantially lower than 21%, elderly patients are significantly more likely to die after this type of surgery, to receive a transfusion, and to experience a prolonged length of stay. • These facts and figures should be discussed at informed consent and a rigorous patient selection is essential.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app